Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biotech plans to enter phase 2.
Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biotech plans to enter phase 2.